Division of Endocrinology and Cardiovascular Discovery Research and Clinical Investigation, Eli Lilly and Company, Lilly Research Laboratories, Indianapolis, IN 46285, USA.
Cell Metab. 2012 Jan 4;15(1):19-24. doi: 10.1016/j.cmet.2011.10.012.
Despite the advent of new drug classes, the global epidemic of cardiometabolic disease has not abated. Continuing unmet medical needs remain a major driver for new research. Drug discovery approaches in this field have mirrored industry trends, leading to a recent increase in the number of molecules entering development. However, worrisome trends and newer hurdles are also apparent. The history of two newer drug classes-glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors-illustrates both progress and challenges. Future success requires that researchers learn from these experiences and continue to explore and apply new technology platforms and research paradigms.
尽管出现了新的药物类别，但全球心血管代谢疾病的流行并未得到缓解。持续存在的未满足的医疗需求仍然是新研究的主要驱动力。该领域的药物发现方法反映了行业趋势，导致最近进入开发阶段的分子数量有所增加。然而，令人担忧的趋势和更新的障碍也显而易见。两种较新的药物类别——胰高血糖素样肽-1 受体激动剂和二肽基肽酶-4 抑制剂的历史——既展示了进展，也展示了挑战。未来的成功需要研究人员从这些经验中吸取教训，并继续探索和应用新技术平台和研究范式。
